Keen Vision Acquisition【KVAC】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

11.16

買値

10.74

売値

17.84

出来高

831

11.14 日の範囲 11.16

10.40 52 週間の範囲 11.16

時価総額

216.125M

前日終値

11.15

始値

11.14

時刻

100

11.16

最終取引時間

財務取引量

US$ 9,266

VWAP

11.15

平均取引量 (3 か月)

9,476

発行済株式数

19,366,000

配当利回り

PER

148.60

1 株当たり利益 (EPS)

0.08

歳入

純利益

1.46M

セクター

Blank Checks

業界

Blank Checks

本社

Road Town, Tortola, Vgb

設立

Keen Vision Acquisition Corporation is listed in the Blank Checks sector of the ナスダック市場 with ticker KVAC. The last closing price for Keen Vision Acquisition was US$11.15. Over the last year, Keen Vision Acquisition shares have traded in a share price range of US$ 10.40 to US$ 11.16.

Keen Vision Acquisition currently has 19,366,000 shares in issue. The market capitalisation of Keen Vision Acquisition is US$215.93 million. Keen Vision Acquisition has a price to earnings ratio (PE ratio) of 148.60.

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping...

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of...

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular...

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology PR...

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating...

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation PR Newswire SUMMIT, N.J. and BOSTON, Sept...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.02	0.179533213645	11.14	11.16	11.09	2782	11.14003163	CS
4	0.06	0.540540540541	11.1	11.16	11.09	5225	11.11446031	CS
12	0.25	2.29147571036	10.91	11.16	10.91	9476	11.02315818	CS
26	0.47	4.3966323667	10.69	11.16	10.67	54016	10.76857369	CS
52	0.74	7.10172744722	10.42	11.16	10.4	54523	10.66386192	CS
156	0.96	9.41176470588	10.2	11.16	10.14	65065	10.50080437	CS
260	0.96	9.41176470588	10.2	11.16	10.14	65065	10.50080437	CS

KVAC - Frequently Asked Questions (FAQ)

What is the current Keen Vision Acquisition share price?

The current share price of Keen Vision Acquisition is US$ 11.16

How many Keen Vision Acquisition shares are in issue?

Keen Vision Acquisition has 19,366,000 shares in issue

What is the market cap of Keen Vision Acquisition?

The market capitalisation of Keen Vision Acquisition is USD 215.93M

What is the 1 year trading range for Keen Vision Acquisition share price?

Keen Vision Acquisition has traded in the range of US$ 10.40 to US$ 11.16 during the past year

What is the PE ratio of Keen Vision Acquisition?

The price to earnings ratio of Keen Vision Acquisition is 148.6

What is the reporting currency for Keen Vision Acquisition?

Keen Vision Acquisition reports financial results in USD

What is the latest annual profit for Keen Vision Acquisition?

The latest annual profit of Keen Vision Acquisition is USD 1.46M

What is the registered address of Keen Vision Acquisition?

The registered address for Keen Vision Acquisition is RITTER HOUSE, WICKHAMS CAY II, PO BOX 3170, ROAD TOWN, TORTOLA, VG1110

Which industry sector does Keen Vision Acquisition operate in?

Keen Vision Acquisition operates in the BLANK CHECKS sector

銘柄コード	株価	出来高
STAKSTAK Inc	US$ 3.97 (156.13%)	173.35k
ORGOOrganogenesis Holdings Inc	US$ 6.21 (102.28%)	58.69M
TRNRInteractive Strength Inc	US$ 2.57 (67.97%)	192.48M
PMAXPowell Max Ltd	US$ 0.511 (43.54%)	136.35M
ARBBARB IOT Group Ltd	US$ 0.6635 (38.23%)	58.86M
NVNINVNI Group Ltd	US$ 0.99 (-50.50%)	72.28M
SPGCSacks Parente Golf Inc	US$ 0.2085 (-48.65%)	57.4M
ADGMAdagio Medical Holdings Inc	US$ 0.8081 (-47.53%)	756.64k
PRAXPraxis Precision Medicines Inc	US$ 38.60 (-40.64%)	3.17M
SAGSAG Holdings Ltd	US$ 1.19 (-38.97%)	788.89k
NVDANVIDIA Corporation	US$ 124.92 (3.97%)	379.97M
TRNRInteractive Strength Inc	US$ 2.57 (67.97%)	192.48M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 13.44 (7.78%)	153.64M
PMAXPowell Max Ltd	US$ 0.511 (43.54%)	136.35M
LCIDLucid Group Inc	US$ 2.22 (-0.45%)	134.28M

銘柄コード

株価

出来高

NVDANVIDIA Corporation

US$ 124.92

(3.97%)

379.97M

TRNRInteractive Strength Inc

US$ 2.57

(67.97%)

192.48M

TSLLDirexion Daily TSLA Bull 2X Trust ETF

US$ 13.44

(7.78%)

153.64M

PMAXPowell Max Ltd

US$ 0.511

(43.54%)

136.35M

LCIDLucid Group Inc

US$ 2.22

(-0.45%)

134.28M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Keen Vision Acquisition Corporation (KVAC)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Keen Vision Acquisition Corporation について

KVAC 最新ニュース

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

KVAC - Frequently Asked Questions (FAQ)

ムーバー

KVAC 財務

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Keen Vision Acquisition Corporation (KVAC) 銘柄情報

Keen Vision Acquisition Corporation (KVAC)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Keen Vision Acquisition Corporation について

KVAC 最新ニュース

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

KVAC - Frequently Asked Questions (FAQ)

ムーバー

KVAC 財務

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する